{"changeSha256":"c7a309bbe2bd4d0f62fb3144c2db1b792a4b214a2f31fa5d5bb03d44c68069f0","changedAt":"2026-11-14","changedFields":[{"after":"A synthetic five-amino-acid peptide that stimulates growth hormone release and is not FDA-approved. FDA’s 2024 review found one small randomized human trial, which showed no significant benefit.","before":"FDA's August 2024 assessment distinguishes ipamorelin free base and acetate and evaluates evidence for growth hormone deficiency and postoperative ileus.","field":"Profile summary"},{"after":"FDA staff recommended in 2024 against adding ipamorelin or ipamorelin acetate to the 503A compounding list, and FDA lists ipamorelin acetate among substances that may present significant safety risks. Ipamorelin is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.","before":"At the time of its assessment, FDA reported that neither form was a component of an FDA-approved drug and found insufficient evidence for the evaluated uses. The advisory briefing is not a final compounding determination.","field":"Evidence note"},{"after":"fda-bulk-peptide-risks, doj-unapproved-peptide-enforcement, fda-ipamorelin-briefing-2024, federal-register-2024-21241-bbe8399c5872, hhs-503a-peptide-enforcement-discretion-notice-2026, hhs-503a-peptide-enforcement-discretion-policy-2026","before":"fda-bulk-peptide-risks, doj-unapproved-peptide-enforcement, fda-ipamorelin-briefing-2024","field":"Cited source records"},{"after":"U.S. Food and Drug Administration [sources: fda-bulk-peptide-risks]; U.S. Department of Health and Human Services [sources: hhs-503a-peptide-enforcement-discretion-notice-2026]","before":"U.S. Food and Drug Administration [sources: fda-bulk-peptide-risks]","field":"Named organizations"},{"after":"name: doj-unapproved-peptide-enforcement; aliases: fda-bulk-peptide-risks; category: fda-bulk-peptide-risks, doj-unapproved-peptide-enforcement; status: doj-unapproved-peptide-enforcement; summary: fda-ipamorelin-briefing-2024; evidenceNote: fda-ipamorelin-briefing-2024, fda-bulk-peptide-risks, hhs-503a-peptide-enforcement-discretion-policy-2026","before":"name: doj-unapproved-peptide-enforcement; aliases: fda-bulk-peptide-risks; category: fda-bulk-peptide-risks, doj-unapproved-peptide-enforcement; status: doj-unapproved-peptide-enforcement; summary: fda-ipamorelin-briefing-2024; evidenceNote: fda-ipamorelin-briefing-2024","field":"Claim citations"}],"currentVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/ipamorelin/versions/3/","version":3},"id":"profile:ipamorelin:v3","interpretationBoundary":"This event describes a PeptideScanner public-version change. It does not by itself establish that the cited source changed, that a scientific conclusion changed, or that source monitoring is continuous.","kind":"profile-updated","notice":"We added a plain-language reader guide with cited answers, re-checked FDA’s ipamorelin briefing and compounding safety-risk page, and noted that HHS’s October 30, 2026 draft enforcement-discretion policy does not include ipamorelin.","peptideSlugs":["ipamorelin"],"previousChangeEvent":{"path":"/corrections/v1/profiles/ipamorelin/v2.json","sha256":"c790c54b0dbcf2f13dec53f8165de84f350fed3004add5fcd422a13e83c12fe0"},"previousVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/ipamorelin/versions/2/","version":2},"schemaVersion":"peptidescanner-public-correction-lineage-event/v1","sourceRecords":[{"id":"fda-ipamorelin-briefing-2024","name":"U.S. Food and Drug Administration","sourceClass":"A","title":"FDA evaluation of ipamorelin-related bulk substances, August 19, 2024","url":"https://www.fda.gov/media/182088/download","verifiedAt":"2026-09-15"},{"id":"fda-bulk-peptide-risks","name":"U.S. Food and Drug Administration","sourceClass":"A","title":"Certain bulk drug substances for use in compounding that may present significant safety risks","url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","verifiedAt":"2026-11-14"},{"id":"hhs-503a-peptide-enforcement-discretion-policy-2026","name":"U.S. Department of Health and Human Services","sourceClass":"A","title":"HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications)","url":"https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf","verifiedAt":"2026-11-14"}],"subject":{"slug":"ipamorelin","type":"profile"}}
